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Abstract
Background: Plasmodium falciparum apical membrane antigen-1 (AMA1) is a leading malaria vaccine candidate
antigen that is expressed by sporozoite, liver and blood stage parasites. Since CD8+ T cell responses have been
implicated in protection against pre-erythrocytic stage malaria, this study was designed to identify MHC class
I-restricted epitopes within AMA1.
Methods: A recombinant adenovirus serotype 5 vector expressing P. falciparum AMA1 was highly immunogenic
when administered to healthy, malaria-naive adult volunteers as determined by IFN-g ELISpot responses to peptide
pools containing overlapping 15-mer peptides spanning full-length AMA1. Computerized algorithms (NetMHC
software) were used to predict minimal MHC-restricted 8-10-mer epitope sequences within AMA1 15-mer peptides
active in ELISpot. A subset of epitopes was synthesized and tested for induction of CD8+ T cell IFN-g responses by
ELISpot depletion and ICS assays. A 3-dimensional model combining Domains I + II of P. falciparum AMA1 and
Domain III of P. vivax AMA1 was used to map these epitopes.
Results: Fourteen 8-10-mer epitopes were predicted to bind to HLA supertypes A01 (3 epitopes), A02 (4 epitopes),
B08 (2 epitopes) and B44 (5 epitopes). Nine of the 14 predicted epitopes were recognized in ELISpot or ELISpot
and ICS assays by one or more volunteers. Depletion of T cell subsets confirmed that these epitopes were CD8+
T cell-dependent. A mixture of the 14 minimal epitopes was capable of recalling CD8+ T cell IFN-g responses from
PBMC of immunized volunteers. Thirteen of the 14 predicted epitopes were polymorphic and the majority
localized to the more conserved front surface of the AMA1 model structure.
Conclusions: This study predicted 14 and confirmed nine MHC class I-restricted CD8+ T cell epitopes on AMA1
recognized in the context of seven HLA alleles. These HLA alleles belong to four HLA supertypes that have a
phenotypic frequency between 23% - 100% in different human populations.
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The sterile protective immunity to malaria induced in
humans by immunization with irradiated sporozoites is
thought to be mediated by CD4+ and CD8+ T cells
responding to malaria peptides expressed on the surface
of hepatocytes or antigen presenting cells by secreting
interferon-gamma (IFN-g) and/or by cytotoxic
responses, although anti-sporozoite antibodies may con-
tribute [1-5]. Many sporozoite and liver stages antigens
have been identified [6] that could play a role in sporo-
zoite and liver stage immunity, including the circum-
sporozoite protein (CSP), the main antigenic component
of the partially protective RTS, S vaccine currently
undergoing Phase 3 testing in sub-Saharan Africa[7,8].
Although CSP contributes to the protection induced by
irradiated sporozoites, it is not required, indicating the
importance of other antigens[9,10]; additionally it has
not been possible to consistently induce CD8+ T cell
responses using recombinant CSP-based vaccines such
as RTS, S[7,11,12]. Combining CSP with other pre-ery-
throcytic stage antigens and using a vaccine platform
such as adenovirus vectors better able to induce class I
restricted cell-mediated immunity might therefore more
effectively target the hepatic stages of infection and
reproduce the immunity induced by the irradiate sporo-
zoite vaccine.
Apical Membrane Antigen-1 (AMA1) is a candidate
antigen for inclusion with CSP in a multi-antigen
malaria vaccine. AMA1 has previously been tested in
several clinical trials as a recombinant protein and eli-
cited both CD4+ and CD8+ T cell responses[13-18].
AMA1 is an integral membrane protein found in all
species of Plasmodium and has traditionally been
regarded as a blood stage antigen, since it is required
for the invasion of red blood cells[19], monoclonal and
polyclonal antibodies targeting AMA1 inhibit blood
stage growth in vitro, naturally acquired anti-AMA1
antibodies correlate with protection against clinical
malaria in endemic areas [20-24], and vaccines based on
AMA1 elicit protection against blood stage infection
[13,25] in animal models that appears to be antibody
mediated [25,26]. However, AMA1 is also expressed in
sporozoites and liver stage parasites[27], and thus may
be a suitable target for CD8+ T cell responses directed
toward liver stage parasites.
To test this hypothesis, two adenovirus-vectored vac-
cines encoding P. falciparum CSP and AMA1 were eval-
uated in a Phase 1 clinical trial. Volunteers were
a d m i n i s t e r e das i n g l ed o s eo ft h em i x e dC S P -a n d
AMA1-encoding constructs (termed the NMRC-M3V-
Ad-PfCA vaccine), either 2 × 10
10 (1 × 10
10 of each con-
struct) or 1 × 10
11 (5 × 10
10 of each construct) particle
units (pu). Robust CD4+ and CD8+ T cell responses
were induced in both low dose and high dose groups
against both antigens, as measured by ex vivo enzyme-
linked immunospot (ELISpot) assay conducted using
pools of 15-mer peptides spanning full length CSP or
AMA1 as the stimulant. These responses were signifi-
cantly higher in the low dose than the high dose group,
and the vaccine consistently induced stronger CD8+ than
CD4+ T cell responses in both groups (Sedegah M, Tam-
m i n g aC ,M c G r a t hS ,H o u s eB ,G a n e s h a nH ,L e j a n oJ ,
Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M,
Manohar N, Richie NO, Wood C, Long CA, Regis D, Shi
M, Chuang I, Spring M, Epstein JE, Mendoza-Silveiras J,
Limbach K, Patterson NB, Bruder JT, Doolan DL, King
CR, Soisson L, Diggs C, Carucci D, Dutta S, Hollingdale
MR, Ockenhouse CF, Richie TL. Multi-stage adenovirus
5-vectored falciparum malaria vaccine elicits CD8+ and
CD4+ T cell responses and limited antibodies in healthy,
seronegative adults, submitted). The CD8+ T cell IFN-g
responses induced in this clinical trial provided the
opportunity to identify the underlying minimal CD8+
T cell epitopes. Frozen peripheral blood mononuclear
cells (PBMC) collected from five volunteers from the
more immunogenic low dose group were therefore
selected for this epitope mapping study.
The crystal structure of the AMA1 ectodomain shows
a conserved central core and variable external loops
formed by Domains I, II and III[28]. About 10% of
amino acids are polymorphic and many of these cluster
within the tertiary structure[28-32] on one external sur-
face and are presumably accessible to antibodies[31,32].
The most polymorphic regions surround a hydrophobic
groove containing cryptic and conserved epitopes[31,32].
A recent study in Mali identified 186 unique AMA1
haplotypes largely varying at these polymorphic sites
[33], while other studies have shown minimal cross-
reactivity among the various allelic variants[17]. This
immune diversity would appear to represent a major
barrier to developing antibody-based vaccines against
AMA1 [26,31,34]. The inhibitory MAb 1F9 maps to
variable epitopes[24] including one site that is also
recognized by a putative receptor for AMA1 binding to
red blood cells[35]. Less is known regarding the most
important T cell epitopes of AMA1, and whether or not
they fall in the regions of highest variability. Previously
identified proliferative AMA1 epitopes in malaria-
exposed individuals in Kenya were mapped to both vari-
able and non-variable regions [36].
Approaches to mapping B and T epitopes have
included using antibodies[37-42], peptides, cell arrayed
polypeptides or phages[36,43-48], computer-based algo-
rithms [49-53] such as NetMHC used in this study[54],
and combinations of these approaches[55]. In this study,
peptide-based mapping and NetMHC algorithms were
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Peptide pools showing positive responses in ELISpot
assays using PBMC from the five most responsive
volunteers from the low dose group were deconvoluted
by testing each individual 15-mer peptide. Next, compu-
terized algorithms in NetMHC software[56] were used
to predict the binding affinities of AMA1 8-10-mer
sequences within the dominant peptides for defined
HLA-A or HLA-B supertypes expressed by each immu-
nized volunteer. A subset of the predicted epitopes was
synthesized, and ELISpot depletion and intracellular
cytokine staining (ICS) assays were performed to con-
firm recall responses by PBMC from the immunized
volunteers and to show their CD8+ T cell-dependence.
A pool of selected minimal epitopes provided a poten-
tially suitable reagent to efficiently measure anti-AMA1
CD8+ T cell responses in genetically diverse popula-
tions. Finally, 10 of the 14 epitopes were localized to the
tertiary structure of AMA1.
Methods
Ethics
This study was conducted according to the Declaration
of Helsinki and the U.S. Code of Federal Regulations
regarding the protection of human participants in
research including The Nuremberg Code, The Belmont
Report, 32 CFR 219 (The Common Rule) and all regula-
tions pertinent to the Department of Defense, the
Department of the Navy, the Department of the Army,
the Bureau of Medicine and Surgery of the United
States Navy and the internal policies for human subject
protections and the standards for the responsible con-
duct of research of the Naval Medical Research Center
(NMRC) and US Army Medical Research and Materiel
Command (USAMRMC). NMRC holds a Department of
Defense/Department of the Navy Federal Wide Assur-
ance for human subject protections, and a Federal Wide
Assurance (FWA 00000152) from the Office for Human
Research Protections (OHRP) for cooperation with the
Department of Health and Human Services. All NMRC
key personnel are certified as having completed manda-
tory human research ethics education curricula and
training under the direction of the NMRC Office of
Research Administration (ORA) and Human Subjects
Protections Program (HSPP). The trial was performed
under US Food and Drug Investigational New Drug
Application BB-IND-13003.
Vaccine and trial design
The NMRC-M3V-Ad-PfCA vaccine used in this study is
a combination of two separate recombinant adenovirus
5 constructs, one expressing full length P. falciparum
CSP (minus 16 repeats, and insertion of 23 amino acids
derived from the 3’-noncoding bovine growth hormone
polyadenylation sequence at the C-terminus) and the
other expressing full length P. falciparum AMA1 (both
strain 3D7). Epitope mapping was conducted using
PBMC taken from volunteers 1 month after administra-
tion of one intramuscular injection of 2 × 10
10 particle
units (pu) of the combination vaccine, unless other
intervals are indicated.
Volunteers and HLA typing
Five of the six immunized volunteers in the low dose
group (v001, v002, v005, v008 and v012) were used in
this study, as v006 gave poor post-immunization
responses. Low to moderate resolution HLA molecular
typing for HLA-A and HLA-B loci (Department of
Defense Bone Marrow Donor Program using specific
oligonucleotide probes to amplify HLA class I and II
genes) provided a list of allelic codes from which it was
possible to tentatively assign each volunteer to an HLA-
A or HLA-B supertype using code lists http://bioinfor-
matics.nmdp.org/HLA/Allele_Codes/Allele_Code_Lists/
index.html (Table 1).
PBMC
PBMC cryopreserved in liquid nitrogen induced com-
parable ELISpot activity as fresh cells (data not shown)
and were used in these experiments. Due to limitation
of the samples collected at 1 month post immunization,
PBMC collected at other time points were used in some
cases (as indicated), as long as responses were still mod-
erately strong.
Peptides and peptide pools
153 15-mer peptides overlapping by 11 amino acids and
spanning the length of AMA1 were synthesized com-
mercially (Mimotopes, VIC, Australia, >80% purity) and
grouped into 12 peptide pools containing 10 to 13 pep-
tides each (Table 2). Seven of these pools (Ap1, Ap3,
Ap4, Ap7, Ap8, Ap10 and Ap11) containing 91 peptides
elicited strong ELISpot responses among the volunteers.
Proliferative T cell epitopes previously identified in
Kenya[36,43] are shown for each peptide pool. All 91
peptides were assayed individually, identifying 16 indivi-
dual 15-mers showing positive ELISpot responses.
Table 1 Volunteer HLA A and B supertypes
Volunteer A Supertype B Supertype
001 A01/A02 B44/B44
002 A01/A02 B08/B44
005 A01/A02 B08/B27
008 A02/A03 B27/B27
012 A01/A03 B44/B58
Low resolution molecular HLA typing permitted identification of the HLA
supertype for each volunteer.
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these 16 15-mers were synthesized (Alpha Diagnostics
Intl. Inc., San Antonio, TX, USA >91% purity) and
tested for recall responses. The positive control was
commercially obtained Class I Peptide Pool Plus (Ana-
spec, USA). Negative control was media with all supple-
ments but no antigen-specific stimulant.
Ex vivo IFN-g ELISpot assays
IFN-g ELISpot assays were conducted as previously
described[57]. Cryopreserved PBMC were suspended in
100 μL complete medium and stimulated with AMA1
peptides in 100 μL of complete medium at a final con-
centration of 10 μg/mL of each peptide tested[57]. Cul-
tures were incubated for 36 hours at 37°C, 5% CO2.
Depending on availability of cells, each PBMC sample
was assayed in duplicate, triplicate, or quadruplicate and
the number of IFN-g-secreting spot forming cells (sfc)
was counted using an automated ELISpot reader (AID,
GmbH, Germany). In duplicate assays, all values were
used in analysis. For triplicate or quadruplicate assays,
outliers were rejected if any single value contributed
more than 50% of the standard deviation of the repli-
cates and if its value was three-fold greater or three-fold
less than the average of the remaining two (or three)
values. The mean number of sfc obtained in negative
control wells was subtracted from the value of each test
well from the same sample. Negative counts generated
by this background subtraction were converted to zero.
The mean number of spots of the test sample was then
calculated and expressed as sfc/million (sfc/m). Based
on testing five volunteers with 91 15-mer peptides,
40 sfc/m was used as a conservative cut-off for deter-
mining positive activity.
Characterization of ELISpot IFN-g-producing cells by T cell
subset depletions
PBMC were depleted of T cell subsets using anti-human
CD4+ or anti-CD8+ coated Dynabeads M-450 (Dynal,
Great Neck, NY) following the manufacturer’si n s t r u c -
tions. Mock depletion was done with Dynabeads coated
with sheep anti-mouse IgG. Flow cytometry confirmed
that T cell subset depletions were >99% in all experi-
ments. Data are presented as the sfc/m and percent
decrease or increase in activity after depletion.
Intracellular cytokine staining (ICS)
ICS was performed as published previously [58]. Cryo-
preserved PBMC were thawed, washed, and resuspended
at 1 × 10
7 cells per mL in complete medium. Peptides
were used at 10 μg/mL and costimulatory antibodies
anti-CD28 and anti-CD4+9 d (BD Bioscience, San Jose,
C A )w e r eu s e da t1μg/mL. Stimulants were added to
cells and incubated at 37°C with 5% CO2 for 2 hours.
Cells were stained with anti-CD3, anti-CD4+, anti-CD8+,
anti-IFN-g, anti-TNF-a, and anti-IL2 and the entire avail-
able sample was acquired on a BD LSRII using FACS-
DiVa (BD Bioscience) software. Data were analysed using
FlowJo Software (Treestar, Inc.). The gating strategy
involved progressively measuring total cells; viable cells;
lymphocytes; T cells; CD4+ CD8+ populations; and
f i n a l l yas p e c i f i cc e l lt y p ee x p r e s s i n gas p e c i f i cc y t o k i n e .
Results were transferred to Prism (GraphPad) for graph-
ing and statistical analysis. Data for peptides were
Table 2 AMA1 peptides used in ELISpot and ICS assays
Pool Amino acids Number peptides Class II T epitope Residues T epitope sequence
Ap1 1-63 13 PL186 14-35 EFTYMIFNGRGQNYWEHPYQKS
PL187 41-51 INEHRPKEY
Ap2 53-115 13 PL188 92-103 NLFSSIEIVERS
Ap3 105-167 13
Ap4 157-219 13 PL189 188-204 PLMSPMTLDEMRHFYKD
Ap5 209-271 13 PL190 218-229 SRHAGNMIPDND
PL191 259-271 NGPRYCNKDE
Ap6 261-323 13 PL192 279-288 AKDISFQNYT
Ap7 313-375 13 PL171 348-366 DQPKQYEQHLTDYEKIKEG
Ap8 365-427 13 PL193 390-402 YKSHGKGYNWGNY
Ap9 417-479 13 PL172 444-461 SLYKNEIMKEIERESKRI
Ap10 469-531 13
Ap11 521-583 13 PL194 527-538 EYKDEYADIPEH
PL173 571-588 GNAEKYDKMDEPQHYGKS
Ap12 573-622 10 PL173 571-588 GNAEKYDKMDEPQHYGKS
PfAMA1 peptide sequences and residue numbers were based on those of the P. falciparum clone FC27 Gene Bank ID 810891. Previously identified class II AMA1
epitopes (see text) were distributed among peptide pools, except pools 3 and 10. Seven immunodominant pools are indicated in bold type.
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total IFN- g from all VD4+ or CD8+ T cells containing
IFN- g either alone or with other cytokines.
NetMHC-based epitope predictions and epitope down-
selection
NetMHC[59] was used to predict HLA class I binding
affinities of 15-mer peptides. NetMHC returns predicted
binding affinity scores that approximate the half maxi-
mal inhibitory concentration (IC50) in nM. Thus, smaller
IC50 values indicate stronger binding. Peptides with
measured binding affinities less than 500 nM IC50 are
considered binders.
Because lengths of typical peptides that bind to HLA
class I molecules range from 8 to 10-mers, binding pre-
dictions were made for all possible 8-10-mers in a 15-
mer. In order to discover a minimal epitope for each
15-mer that induced a CD8+ response, the peptide with
the strongest predicted binding affinity for a given HLA
allele was selected.
In practice, because of the low resolution of HLA typ-
ing data available for the volunteers, peptide binding
predictions were made for all alleles that matched the
provided data. For example, the HLA typing data indi-
cates that volunteer v001 has an allele that belongs in
the A02 supertype. The HLA typing data also provided
a list of possible alleles that belong in the same super-
type, which includes A*0201, A*0207 and A*0209. Pep-
tide binding predictions were made for each allele,
provided a predictor was available. Thus, for each
15-mer, the strongest predicted binder out of all 8-
10-mer peptides across different possible alleles and its
predicted binding affinity were recorded. This strongest
predicted binder is referred to as the predicted minimal
epitope. In the end, a single predicted minimal epitope
was associated with each 15-mer after ranking candi-
dates by binding affinity predictions.
Epitope mapping on the AMA1 3 D structure
The P. falciparum AMA1 Domains I and II model 1Z40
was fitted onto the P. vivax AMA1 Domain I, II and III
model 1w81 (E chain) using Swiss Pdb-Viewer software
[Swiss Institute of Bioinformatics (Basel, Switzerland)].
The final 3 D model was generated by combining
Domains I and II of the P. falciparum AMA1 model
with Domain III of the P. vivax AMA1 model, omitting
Domains I and II of the P. vivax AMA1 model. Accessi-
bility of the amino acid residues was determined by the
same software.
Results
Volunteers
The five volunteers used in this study expressed a total
of seven supertypes (Table 1), A01, A02, A03, B08, B27,
B44 and B58, representing three of the six HLA-A and
four of the six HLA-B supertypes[60]. Together these
cover 100% of the Caucasian population, 27% or the
African American population, and a variable per cent of
sub-Saharan populations according to their genetic
diversity[61]. There were no volunteers with other high
frequency supertypes such as A24 or B07[61].
Identification of AMA1 15-mer peptides most active in
ELISpot assay
The 91 15-mers contained within peptide pools Ap1,
Ap3, Ap4, Ap7, Ap8, Ap10 and Ap11 were tested indivi-
dually by ELISpot assay using PBMC from 1 month post
immunization. Sixteen peptides were recognized by one
or more of the five volunteers at levels > 40 sfc/m, and
assigned numbers of 1-16 (Table 3). Some were recog-
nized by more than one volunteer such as peptide 14 in
pool 8 (Ap8-11) that was recognized by v001, v005 and
v008.
ELISpot assays with 15-mer peptides after depletion of
CD4+ and CD8+ T cells
In these depletion studies, the availability of PBMC from
1 month following immunization limited assays to five
of the sixteen 15-mers and four of the volunteers listed
in Table 3 (v008 excluded). CD8+ T cell depletion
reduced ELISpot activity by 56-100% (Table 4) demon-
strating the presence of at least one minimal CD8+-
restricted epitope within each 15-mer tested for each of
the four volunteers that was recognized in the context
of supertypes A1, B44 or B08. As shown in Table 3,
peptide 3 was recognized by v002 and v005, and peptide
16 by v001 and v012, and this is attributed to common
HLA alleles between these volunteers (Table 1). In those
cases where depletion of CD4+ T cells also reduced ELI-
Spot responses, the effect was much smaller (0-57%)
than for CD8+ T cells, suggesting that these peptides
contain predominantly CD8+ T cell epitopes. Depletion
of CD4+ T cells led to an increase in ELISpot activity
with v001, suggesting the removal of suppressor
mechanisms.
NetMHC prediction of class I-restricted epitopes in AMA1
15-mer peptides
NetMHC predicted a series of HLA-A- and B-restricted
8-10-mer epitopes within the 16 15-mers active in ELI-
Spot assays (Table 5). Each predicted epitope was
restricted by a specific HLA allele but since the HLA
typing of the volunteers was low to moderate resolution,
this study selected the best binders for the several candi-
date alleles within each volunteer’s HLA supertype. For
example, peptide 1 contained a predicted epitope
restricted by HLA B*1801 that matched the v001 HLA
supertype B44 as shown in Table 5. Since overlapping
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were contained in more than one peptide, for example
epitope E3 was contained in two overlapping peptides 3
and 4 (Table 5). Furthermore, there was also one case
where one 15-mer peptide, peptide 14, contained 2
predicted epitopes, E11 and E12, leaving a net of 14
unique epitopes.
Nine of the 14 resulting epitopes (64%) were classified
as strong binders (<500 nM). Of these 14 minimal epi-
topes, two were predicted to be restricted by HLA-
Table 3 ELISpot IFN-g activity of AMA1 peptide pools and individual 15-mer peptides within these pools
Pool Vol. sfc/m 15-mer peptide Amino acid number Sequence sfc/m Peptide number
Ap1 001 119 Ap1-3 9-23 LLSAFEFTYMINFGR 48 1
Ap1 001 119 Ap1-9 33-47 QNSDVYRPINEHREH 48 2
Ap1 002 161 Ap1-11 41-55 INEHREHPKEYEYPL 180 3
Ap1 005 325 Ap1-11 INEHREHPKEYEYPL 322
Ap1 002 161 Ap1-12 45-59 REHPKEYEYPLHQEH 66 4
Ap1 005 325 Ap1-12 REHPKEYEYPLHQEH 118
Ap1 001 119 Ap1-13 49-64 KEYEYPLHQEHTYQQ 42 5
Ap4 005 208 Ap4-5 173-187 NQYLKDGGFAFPTE 50 6
Ap4 002 208 Ap4-9 189-203 LMSPMTLDEMRHFYK 189 7
Ap4 005 310 Ap4-9 LMSPMTLDEMRHFYK 395
Ap4 002 208 Ap4-10 193-207 MTLDEMRHFYKDNKY 82 8
Ap4 005 208 Ap4-10 MTLDEMRHFYKDNKY 118
Ap4 005 208 Ap4-11 197-211 EMRHFYKDNKYVKNL 65 9
Ap7 001 131 Ap7-3 310-324 EDIPHVNEFPAIDLF 139 10
Ap7 001 131 Ap7-4 314-328 HVNEFPAIDLFECNK 96 11
Ap7 001 131 Ap7-7 336-350 CNKLVFELSADQPK 77 12
Ap8 012 138 Ap8-6 384-398 FKADRYKSHGKGYNW 143 13
Ap8 001 78 Ap8-11 405-419 ETQKCEIFNVKPCL 48 14
Ap8 005 156 Ap8-11 ETQKCEIFNVKPCL 218
Ap8 008 78 Ap8-11 ETQKCEIFNVKPCL 48
Ap8 005 156 Ap8-12 409-423 CEIFNVKPTCLINNS 127 15
Ap10 001 172 Ap10-13 517-531 TSNNEVVVKEEYDE 233 16
Ap10 012 193 Ap10-13 TSNNEVVVKEEYDE 250
A total of 16 individual peptides were identified from a total of 91 15-mer peptides from seven active pools. Peptides Ap1-11, Ap1-12, Ap4-9, Ap4-10, Ap8-11 and
Ap10-13 stimulated strong responses in more than one volunteer.
Table 4 ELISpot IFN-g activity of AMA1 15-mer peptides after depletion of CD4+ and CD8+ T cells
Vol. Pool Peptide number* Sequence Control depletion sfc/m CD4 depletion
sfc/m (%)
CD8 depletion sfc/m (%)
001 Ap1 155 222 (+43%) 55 (-65%)
1 LLSAFEFTYMINFGR 85 58 (-32%) 37 (-56%)
5 KEYEYPLHQEHTYQQ 72 168 (+133%) 17 (-76%)
16 TSNNEVVVKEEYDE 103 252 (+148%) 13 (-88%)
002 Ap1 187 148 (-21%) 5 (-97%)
3 INEHREHPKEYEYPL 185 152 (-18%) 11 (-94%)
005 Ap1 267 173 (-35%) 11 (-96%)
3 INEHREHPKEYEYPL 233 145 (-37%) 0 (-100%)
Ap4 273 117 (-57%) 0 (-100%)
7 LMSPMTLDEMRHFYK 204 137 (-32%) 1 (-100%)
012 Ap10 48 37 (-23%) 0 (-100%)
16 TSNNEVVVKEEYDE 79 90 (+14%) 0 (-100%)
The percent change in ELISpot activity is shown after depletion of CD4+ or CD8+ T cells. Depletion of CD8+ T cells reduced ELISpot activity by 56-100%, whereas
CD4+ T cell depletion reduced activity by no more than 57%. Although this suggested that the primary epitopes within these peptide pools and 15-mers are
CD8+ T cell epitopes, some peptides may also contain CD4+ T cell epitopes. v001 and v012 showed an increase in ELISpot activity after CD4+ T cell depletion
that may indicate the removal of regulatory T cells that had been suppressing CD8+ T cell activity.
* See last column of Table 3.
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Page 6 of 16A*0101 and one by HLA-A*3002 (A01 supertype); two
by HLA-A*0201 and two by HLA-A*6802 (A02 super-
type); two by HLA-B*0801 (B08 supertype); four by
H L A - B * 1 8 0 1a n do n eb yH L A - B * 4 4 0 2( B 4 4s u p e r t y p e ) .
Epitopes predicted to bind to supertypes A03, B27 and
B58 present in the volunteers were not identified.
ELISpot activity of predicted minimal epitopes compared
to parent peptide pool
PBMC available from bleeds at 4 months had similar
activity to those at 1 month for v001 and v002 and
were, therefore, used for the evaluation of epitopes E1,
E2, E3, E4, E6, E8, E9, E12 and E14. ELISpot activity of
these predicted minimal epitopes compared favorably to
the ELISpot activity of parent peptide pool activity for
all nine (Table 6). Availability of PBMC from v005 and
v008 was more restricted, and their ELISpot activity was
too low to allow evaluation of E5, E7, E11 and E13.
PBMC from v012 taken 7 months post-immunization
confirmed positive responses for E8 and E14 but sug-
gested that E10, where responses were ten-fold less than
the parent peptide pool and below the cut-off of 40 sfc/
m, did not constitute the minimal epitope for that
volunteer. Therefore, nine of the predicted epitopes
were recognized by one or more volunteers, four could
not be adequately tested and one was not recognized.
Of the nine confirmed epitopes, six had strong predicted
binding affinities (< 500 n M )a n dt h r e ew e r e> 5 0 0n m
(Table 5).
Table 5 Predicted CD8+ T cell-restricted epitopes within AMA1 15-mer peptides specific for each volunteer
Peptide number Predicted epitope Amino acid
number
IC50 nM HLA restriction HLA supertype Epitope number
1 LLSAFEFTYMINFGR 13-21 5 B*1801 B44 E1
2Q N SDVYRPINEHREH 35-44 14991 B*4402 B44 E2
3 INEHREHPKEYEYPL 47-55 18 B*0801 B08 E3
4R E HPKEYEYPLHQEH
5K E YEYPLHQEHTYQQ 51-59 39 B*1801 B44 E4
6N Q YLKDGGFAFPTE 175-183 142 B*0801 B08 E5
7 LMSPMTLDEMRHFYK 194-202 17 A*0101 A01 E6
8M TLDEMRHFYKDNKY
9E MRHFYKDNKYVKNL 198-207 4742 A*0101 A01 E7
10 EDIPHVNEFPAIDLF 327-335 7 B*1801 B44 E8
11 HVNEFPAIDLFECNK
12 CNKLVFELSADQPK 339-346 5708 A*0201 A02 E9
13 FKADRYKSHGKGYNW 389-397 201 A*3002 A01 E10
14 ETQKCEIFNVKPCL 405-414 142 A*6802 A02 E11
ETQKCEIFNVKPCL 406-414 919 A*0201 A02 E12
15 CEIFNVKPTCLINNS 410-419 617 A*6802 A02 E13
16 TSNNEVVVKEEYDE 520-528 15 B*1801 B44 E14
The 15-mer peptides that were recognized by the volunteers (Table 3) were analysed by NetMHC web-based software to predict potential high affinity HLA
binding by minimal CD8+ T cell epitopes within each 15-mer. Each minimal epitope was specific for a known HLA allele within each supertype. Those minimal
epitopes with the strongest binding affinities for the HLA supertype of each volunteer were selected. The Table shows the minimal epitopes in bold. Two
different HLA-restricted epitopes were predicted with peptide 14.
Table 6 ELISpot IFN-g activity of the original peptide pool
and the derived 8-10-mer epitopes
Epitope
number
Sequence HLA
supertype
sfc/m Pool sfc/m Vol.
E1 FEFTYMINF B44 121
4m Ap1 133
4m 001
E2 SDVYRPINEH B44 114
4m Ap1 133
4m 001
E3 HPKEYEYPL B08 69
4m Ap1 96
4m 002
E4 YEYPLHQEH B44 222
4m Ap1 133
4m 001
E5 YLKDGGFAF B08 9
10d Ap4 46
10d 005
E6 TLDEMRHFYK A01 51
4m Ap4 114
4m 002
E7 MRHFYKDNKY A01 15
10d Ap4 46
10d 005
E8 NEFPAIDLF B44 224
4m Ap7 200
4m 001
-- - 4 9
7m Ap7 80
7m 012
E9 KLVFELSA A02 169
4m Ap7 200
4m 001
E10 RYKSHGKGY A01 11
7m Ap8 108
7m 012
E11 ETQKCEIFNV A02 21
10m Ap8 57
10m 008
E12 TQKCEIFNV A02 172
4m Ap8 104
4m 001
E13 EIFNVKPTCL A02 37
10m Ap8 57
10m 008
E14 NEVVVKEEY B44 344
4m Ap10 155
4m 001
- - - 104
7m Ap10 151
7m 012
Synthetic peptide 8-10-mers were tested in ELISpot assay using PBMC
collected 10 days (v005), 4 months (v001, v002), 7 months (v012) or 10
months (v008) following immunization (PBMC collected at 1 month were no
longer available). Activity was measured as sfc/m. Nine of the 14 epitopes (E1,
E2, E3, E4, E6, E8, E9, E12 and E14) were confirmed as positive using the
parent peptide pool as controls, in most cases recalling responses equivalent
to those recalled by the parent peptide pool (epitope number and sequences
in bold). Four of the epitopes (E5, E7, E11, E13) did not meet the 40 sfc/m
cut-off but these results were not considered meaningful as the responses of
the parent peptide pools were only marginally positive. The parent peptide
pool for E10 recalled 108 sfc/m while the responses to the peptide were
much lower (11 sfc/m), suggesting that E10 may not be correctly identified.
Assays where the parent peptide pool did not exceed the cut-off of 40 sfc/m
were not included in the table (see Methods).
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assays to measure total IFN-g from CD4+ and CD8+
T cell subsets in response to selected minimal epitopes
and parent peptide pools (Figure 1). These assays
showed that the frequency of CD8+ T cells producing
total IFN-g was far greater than that of CD4+ T cells.
Four epitopes (E3, E6, E8 and E14) induced equal or
more CD8+ IFN-g than the parent peptide pool,
whereas two epitopes (E10 and E11) induced weak CD8
+I F N - g responses. PBMC were insufficient to perform
assays for the other epitopes. These results supported
the identification, as minimal MHC class I epitopes, of
E3, E6, E8 and E14, while E10 and E11 could not be
confirmed.
ICS CD4+ and CD8+ T cell multifunctional responses to
AMA1 peptide pools and minimal epitopes
The pattern of multifunctional CD8+ T cell responses
(defined as cells expressing two or more cytokines)
recalled by each minimal epitope (Figure 2) were gener-
ally similar to that of total CD8+ IFN-g responses
(Figure 1), although they were lower. Concordant with
total IFN-g responses, epitopes E10 and E11 did not
appear to induce multifunctional responses with v008
and v012.
ELISpot assays with epitope mixture AMA1-14e, single
AMA1 pool, individual pools and individual epitopes
The feasibility of using pooled epitopes to evaluate CD8
+ T cell responses to AMA1 was investigated to
establish that non-binding epitopes did not block speci-
fic HLA-restricted binding. Three volunteers who con-
sistently gave high responses to peptide pools were
tested with four different stimulants: (1) Ap1-Ap12: all
153 15-mer peptides at 1.25 μg/mL; (2) AMA1-14e: the
14 predicted epitopes mixed and tested at 10 μg/mL;
(3) 15-mer peptide pools at 10 μg/ml that were strongly
recognized by these volunteers; (4) The predicted epi-
tope at 10 μg/ml within those selected 15-mer peptide
pools previously shown to have ELISpot activity. As
shown in Figure 3, AMA1-14e was as active or nearly as
active in inducing ELISpot responses as a mixture of all
153 15-mers (Ap1-Ap12).
Figure 1 AMA1 peptide pools and minimal epitopes elicit ICS
CD4+ and CD8+ T cell IFN-g responses. AMA1 peptide pools (P)
and associated minimal CD8+ T epitopes (E) were tested in ICS
assays using PBMC collected 10 days (v005), 4 months (v001, v002),
7 months (v012) or 10 months (v008) following immunization.
Activity was measured as % cytokine producing CD4+ and CD8+ T
cells producing IFN-g.
Figure 2 AMA1 peptide pools and minimal epitopes elicit ICS
CD4+ and CD8+ T cell multifunctional responses. AMA1 peptide
pools (P) and associated minimal CD8+ T epitopes (E) were tested
in ICS assays using PBMC collected 10 days (v005), 4 months (v001,
v002), 7 months (v012) and 10 months (v008) following
immunization. Multifunctional activity was measured as % cytokine
producing CD4+ and CD8+ T cells producing at least two cytokines
among IFN-g, TNF-a and IL-2.
Figure 3 AMA1-14e is as active in ELISpot as peptide pools and
minimal epitopes. PBMC from each volunteer were tested in ELISpot
assays with Ap1-12 (mixture of 153 15-mer overlapping peptides),
AMA1-14e (mixture of 14 minimal epitopes), Ap1 or Ap10, and
individual epitopes (consistent with that volunteer’s HLA supertype -
NEVVVKEEY is E14 and HPKEYEYPL is E3). AMA1-14e was as active as
Ap1-12 with v002 and v005 and nearly as active with v001. Bars
represent standard deviation of the mean response (duplicates).
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with epitope mixture AMA1-14e
CD8+ T cell depletion reduced ELISpot activity to
AMA1-14e by about 85% - 95% in the two volunteers
tested, v001 and v005, and AMA1-14e much more
strongly induced CD8+ than CD4+ T cell IFN-g by ICS
assay. In contrast, Ap1-Ap12 induced both CD4+ and
CD8+ T cell responses, whereas AMA1 recombinant
protein only recalled CD4+ T cell responses (Figure 4).
Thus AMA1-14e may be a suitable reagent to demon-
strate CD8+ T cell immunogenicity of AMA1-based
vaccines in vaccine trials where volunteers have HLA
alleles matching the epitopes in AMA1-14e.
Localization of the predicted minimal epitopes within
AMA1
E1 lies within the signal domain, E2, E3, E4 within the
prodomain, E5, E6 and E7 within Domain I, E8, E9,
E10, E11, E12 and E13 within Domain II, and E14
within Domain III (Table 7). Three of the 14 predicted
CD8+ minimal epitopes were fully or partially within
proliferative epitopes identified in Kenya: E1 and PL186;
E6 and PL189; E10 and PL193. The other 11 predicted
epitopes were largely or wholly independent of these
proliferative epitopes.
Based on the sequence of AMA1[26], epitopes E2, E3,
E 4 ,E 5 ,E 6 ,E 7 ,E 8 ,E 1 0 ,E 1 1a n dE 1 2a r ev a r i a b l e ,E 9 ,
E13, E14 have a low frequency (< 0.001%) of variable
residues, whereas E1 is conserved. There are disulphide
bonds between several cysteines (C) that form loops;
epitopes E5, E6 and E7 are contained in a C-C loop in
Domain I, and E8, E9, E10, E11, E12 and E13 are in a
C-C loop in Domain II. Since all of these epitopes in
C-C loops are variable, it is likely that they are exposed
on the surface[32]. This was confirmed by mapping
these epitopes to a model structure of AMA1, con-
structed from P. falciparum Domains I and II, and
P. vivax Domain III[28,31,32]. The signal and prodo-
main containing E1-E4 were not contained in this
model. The localization of epitopes E5-E14 is shown in
Figure 4 ELISpot activity against AMA1-14e after CD4+ or CD8+ T cell depletion. PBMC from v001 and v005 were tested in IFN-g ELISpot
assays after CD4+ or CD8+ T cell depletion (top panel), and in ICS assay for total % CD4+ or CD8+ T cell IFN-g (lower panel), with Ap1-12 (all
153 15-mer peptides), AMA1-14e, and AMA1 recombinant protein (AMA rp). ELISpot depletion and ICS assays show that AMA1-14e and Ap1-12
are both strongly recognized by CD8+ T cells. However, recombinant AMA1 protein is preferentially recognized by CD4+ T cells.
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Page 9 of 16Figure 5 and Table 7. Epitopes E8, E9, E10, E12, E13
and part of E14 form a continuous cluster on the front
face, E5, E7, E8 and E9 wrap around from the front to
back faces, and E6 (largely) and E11 localize to the back
face. E5, though not confirmed as an epitope, is largely
non-variant and immediately adjacent to the conserved
hydrophobic cleft, whereas E6 is in a hypervariable
region of Domain I also adjacent to the cleft. E7 is con-
tiguous with E6 as might be expected from their over-
lapping sequences (Table 7). E9 is close to the binding
site of inhibitory MAb 4G2 and contiguous with E10
that contains R389 that is essential for 4G2 binding[20].
E12 appears to be clustered with E8 and E9 although it
is 60 amino acids C-terminal to E9, and close to E13.
As expected from the linear sequences E11 appears to
be adjacent to E12 but on the back face. Unexpectedly
from the linear sequence, E14 is close to E13 and adja-
cent to the large cluster formed by E8, E9, E10, E12,
E13 and part of E14.
Epitope polymorphism and surface accessibility
The polymorphic residues in all 14 epitopes are shown
in Table 7. Only E1 is completely non-variant, although
the frequencies of single amino acid polymorphisms in
E9, E13 and E14 are rare (<0.001%). Overall there are 27
polymorphic residues in all 14 epitopes. For E5-E14 that
could be mapped, there are 18 polymorphic residues of
which 16 are surface accessible (Table 7). Thus, E6 con-
tains variable amino acids at positions D196,E 197,R 199,
H200 and F201, and all except R199 are accessible to the
surface. Overall, R199 and S345 in these epitopes are
polymorphic but not surface accessible. However, there
are 10 amino acids that are surface accessible that are
not polymorphic such as T406 and N413 in E12. There-
fore polymorphic residues are mostly surface accessible,
but there are other surface accessible residues that are
not polymorphic.
Discussion
The aim of this study was to identify class I epitopes
underlying the CD8+ T cell IFN-g responses observed
on ELISpot and ICS assays following administration of
the NMRC-M3V-Ad-PfCA adenovirus-vectored P. falci-
parum malaria vaccine. Mapping class I epitopes was
pursued to better understand the immune responses
induced by AMA1 and to guide the development of a
broadly protective malaria vaccine for a genetically
diverse human population.
To map the epitopes, low to mid level HLA typing
was performed to determine the HLA A and B super-
type for each of five immunized volunteers. Subse-
quently, all possible 8-10 amino acid sequences from
15-mer AMA1 peptides inducing recall responses on
ELISpot assay were evaluated in silico using NetMHC
software, and ranked for binding affinity to the A and B
alleles. Predicted top-binding epitopes were synthesized
and ELISpot and ICS assays were used to confirm epi-
tope identification by demonstrating that (1) the pre-
dicted epitope recalled IFN-g responses as effectively as
the parent peptide pool, (2) the responses of the parent
Table 7 Summary of the properties of AMA1 epitopes
Epitope HLA-restriction Amino acids Sequence Location Crystal
face
Accessibility
E1 B44 13-21 FEFTYMINF Signal
E2 B44 35-44 SDVYRPINEH Prodomain
E3 B08 47-55 HPKEYEYPL Prodomain
E4 B44 51-59 YEYPLHQEH Prodomain
E5 B08 175-183 YLKDGGFAF Domain I F/B Y
naKD
E6 A01 194-202 TLDE
+MRHFY Domain I B D, E, H, F
E7 A01 198-207 MRHFYKDNKY Domain I F/B H, F, D, K, Y
E8 B44 327-335 NEFPAIDLF Domain II F/B E, P, I
E9 A02 339-346 KLVFELS*A Domain II F E, L
E10 A01 389-397 RYKSHGKGY Domain II F H, K, Y
E11 A02 405-414 ETQKCEIFNV Domain II B E, T, Q, N
E12 A02 406-414 TQKCEIFNV Domain II F T, Q, N
E13 A02 410-419 EIFNVK*PTCL Domain II F NK
E14 B44 520-528 NEVVVKE*EY Domain III F VEE
Variable amino acids are highlighted in bold.
*Indicated that there is only one variant of <0.001% frequency
E
+ is essential for binding of growth inhibitory MAb 1F9
F = front, B = back, F/B = wraps from front to back
Y
na Accessibility not available for amino acid Y
Confirmed epitope numbers are indicated in bold
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Page 10 of 16Figure 5 Location within model of AMA1 crystal structure of 10 predicted HLA-A and HLA-B epitopes. Spatial distribution of CD8
epitopes on the 3 D model structure of AMA1. The structure of PfAMA1 Domain I and II (1Z40) was fitted on the structure of PvAMA1 Domain
I, II and III (1wk8), using Swiss Pdb-Viewer software http://www.expasy.org/spdbv/. Domain I and II of the PfAMA1 structure (light grey regions)
and Domain III of PvAMA (dark grey region) are visible. Panels A & C show front view (largely conserved), B & D show back view (more
polymorphic). Confirmed CD8 epitopes (E6, E8, E9, E12, E14) are orange in panels A & B, non-confirmed epitopes (E5, E7, E10, E11, E13) are
yellow, while overlapping confirmed epitopes and non-confirmed epitopes are also in orange. Residues that are conserved among malaria
species are shown in red and those that are polymorphic are shown in blue. Light grey (PfAMA) and dark grey (PvAMA1) are residues that differ
between these species. Arrows point to individual epitopes. Overlapping epitopes may be indicated by multiple arrows. Confirmed epitopes E1
to E4 (see text) are not shown, as the part of the protein where these epitopes reside is not present in this crystal structure model.
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assay, and (3) the epitopes themselves stimulated IFN-g
production by CD8+ T cells on ICS assay.
Using this approach, sixteen 15-mer peptides were
down-selected from the peptide pools on the basis of
stimulating positive recall responses by ELISpot assay
from the immunized volunteers. NetMHC predicted 14
class I 8-10-mer epitopes lying within these peptides for
t h ef i v ev o l u n t e e r s .N i n eo ft h e s ew e r es h o w nb yE L I -
S p o ta s s a yt ob ea c t i v e( E 1 ,E 2 ,E 3 ,E 4 ,E 6 ,E 8 ,E 9 ,E 1 2
and E14), eliciting IFN-g responses comparable to those
elicited by the parent peptide pools, while four could
not be adequately assessed as the PBMC eliciting strong
recall responses for these volunteers were no longer
available (E5, E7, E11, E13), and one induced low recall
responses relative to the parent peptide pool (E10).
To further evaluate the predicted epitopes, ELISpot
depletion assays were conducted by stimulating PBMC
from four volunteers with three parent peptide pools
(Ap1, Ap4, Ap10) or with five individual 15-mer
p e p t i d e sf r o mt h o s ep o o l s( 1 ,3 ,5 ,7 ,1 6 ) .T h e1 5 - m e r s
contained, respectively, the epitopes E1, E3, E4, E6 and
E14. CD8+ T cell depletion reduced responses in five
tests of the three peptide pools by 65%, 97%, 96%, 100%
and 100%, respectively, and to the five 15-mers by 56-
100% (mean of 88%). In contrast, depleting CD4+
T cells increased activity in Ap1 and two of the three
peptides it contained as well as one peptide in Ap10,
and reduced the ELISpot activity recalled by the remain-
ing peptides by only 18- 37% (mean of 30%), strongly
supporting the contention that the selected 15-mers
contained minimal class I epitopes.
ICS assays performed using six minimal epitopes
showed that four could recall IFN-g responses from
CD8+ T cells (E3, E6, E8 and E14), while two could not
(E10 and E11). In contrast IFN-g responses from CD4
cells were minimal or absent when stimulating with the
same minimal epitopes.
I ns u m m a r y ,o ft h en i n ee p i t o p e sa c t i v eb yE L I S p o t
(E1, E2, E3, E4, E6, E8, E9, E12 and E14), subsequent
ELISpot depletion assays support the identification of
E1, E3, E4, E6 and E14 and ICS assays the identification
of E3, E6, E8 and E14, while E2, E9 and E12 could not
be adequately assessed due to PBMC supplies. Four
additional epitopes (E5, E7, E11 and E13) have yet to be
confirmed as class I-restricted by testing for reductions
in ELISpot responses on CD8+ T cell depletion or by
testing for CD8+ T cell responses on ICS assay. The
remaining epitope, E10, recalled only 10% of the
response recalled by the parent peptide pool on ELISpot
assay and was not active on ICS assay, and thus may
not be correctly identified.
While the focus of these experiments was induction of
IFN-g in ELISpot or ICS assays, four epitopes (E3, E6,
E8 and E14) demonstrated recall of multifunctional
responses (production of at least two cytokines of IFN-g,
TNF-a and IL-2) that might, due to the higher IFN-g
secretion levels in multifunctional T cells, contribute
disproportionately to the overall IFN-g response at 1
month following immunization, acting as more potent
immune effectors.
Developing a reagent for class I responses to AMA1
The 14 putative minimal class I epitopes were combined
into a reagent pool, denoted AMA1-14e, and this pool
was shown to be an efficient stimulant for recalling
T cell responses to AMA1. The AMA1-14e pool stimu-
lated responses equivalent to parent 15-mer peptides
and peptide pools, and these responses were CD8+
T cell-dependent by ELISpot depletion assay. Future
trials with the NMRC-M3V-Ad-PfCA vaccine should
reveal the usefulness of the AMA1-14e reagent. A pre-
vious study using DNA plasmids containing five malaria
candidate vaccine genes relied on using HLA-matched
peptides[62]; an HLA-diverse reagent similar to AMA1-
14e would have greatly simplified this approach.
Population coverage associated with the identified
epitopes
The 14 epitopes identified in this study were character-
ized with regard to the coverage provided for the HLA
diverse human population. The epitopes were restricted
by four of the seven HLA supertypes expressed by the
volunteers: A01, A02, B08 and B44. MHC class 1 mole-
cules from the other supertypes identified in the volun-
teers, A03, B27 and B58, may also have recognized
AMA1 CD8+ T cell epitopes. Such epitopes binding to
these allelic supertypes were predicted by NetMHC, but
were not located within the 15-mers recalling the stron-
gest responses by ELISpot assay, and thus were not
synthesized or tested. A01, A02, B08 and B44 supertypes
cover approximately 100% of Caucasian populations and
27% of US African Americans [61]. Therefore, to reach
nearly 100% coverage, particularly of sub-Saharan Afri-
cans, other epitopes restricted by the prevalent super-
types A03, A24, B07 and B58 need to be identified.
Previous observations identified 11 proliferative T cell
epitopes in Kenya[36], one of which was associated with
lower risk of parasitaemia[43]. Since these were long
peptides (12-22 amino acids) they may contain CD4+ or
CD8+ T cell epitopes.
Epitope variability and location within the AMA1 crystal
structure
The structures of Domains I, II and III of P. falciparum
AMA1 are relatively conserved among Plasmodium
species [26,28], but there is nevertheless extensive poly-
morphism present as well [63-65], reflected by the
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Many of the previously defined proliferative epitopes
(Table 2) map to variant regions of the protein [36,43].
The 14 putative class I epitopes predicted in this study
were compared to available sequence data on AMA1
[26], and this analysis showed that 13 of the 14 epitopes
likewise contained one or more polymorphic amino
acids (all except E1), although three were variable at a
low level (<0.001%) (E9, E13 and E14).
A model of the crystal structure of AMA1 was gener-
ated to allow localization of ten of the 14 epitopes
within the tertiary structure (Figure 5). This is one of
the first studies in which CD8+ T cell epitopes, rather
than antibody epitopes, have been localized in this way.
Many of the ten epitopes clustered together on the front
face, whereas a few wrapped around from the front to
back or were localized on the back face. Surface location
was a surprising finding, since it is generally thought
that class I-restricted epitopes occur independently
of surface exposure. Surface location of T epitopes
has been previously described in HIV where it was
suggested that this resulted in increase accessibility to
the antigen-processing pathway [67].
Epitope E6 localized to a hyper-variable region of
AMA1 on the back of the molecule, adjacent to the
putative hydrophobic cleft[32] and E197, one of the vari-
able residues in E6 (see E197 in Table 7), is crucial to
the binding of the growth inhibitory MAb 1F9 and also
forms part of a putative AMA1 receptor[35]. E197 is also
contained within the variable epitope 189 identified in
Kenya[36].
Amino acid polymorphism in AMA1 is associated
with surface accessibility, whether on the front or back
face. Immune pressure may have driven polymorphism
in residues surrounding the putative binding site in the
hydrophobic cleft[31]. Other studies have attributed
polymorphism within T cell epitope regions to host eva-
sion of T cell recognition irrespective of molecular func-
tion [26,34,68] in which parasite strains are favored
through reduced affinity of molecular sequences for
binding to HLA A or B alleles[31]. An association
between immune pressure and T cell epitope variability
has been proposed for other malaria antigens such as
CSP and will need to be overcome for successful vaccine
development[14,34]. In one study, a diversity-covering
approach that took into account genetic linkages among
polymorphic sequences improved allelic recognition by
ELISA and growth inhibitory antibodies for AMA1[69],
and may also be applicable to T cell-dependent AMA1
vaccines.
Four HLA-B8/B44-restricted epitopes are close to the
N-terminal in the signal sequence and prodomain (E1-
E4), while seven of the 10 remaining epitopes are HLA-
A1/A2-restricted. The signal sequence and prodomain
are cleaved off first during merozoite release and red
cell invasion[70] during which AMA1 re-localizes
around the merozoite surface, and then Domains I and
II and part of Domain III are shed as the merozoite
invades[26]. It is therefore possible that this sequence of
events influences AMA1 uptake by antigen-presenting
cells, such that epitopes in the signal sequence and pro-
domain may be presented to HLA-B-restricted T cells,
while the later shedding of the domains favors presenta-
tion to HLA-A-restricted T cells. It is also interesting
that the single non-polymorphic epitope E14 is located
in the part of Domain III which remains on the mero-
zoite during invasion.
Conclusions
This study identified fourteen putative minimal CD8+
T cell-dependent epitopes within AMA1 that are
restricted by four HLA supertypes that together are
expressed by 100% of Caucasians, but only 27% of Afri-
can Americans. Nine epitopes were confirmed using
ELISpot or ELISpot and ICS assays. Some of these
clustered on the front face of AMA1, while others were
more randomly distributed but still mostly surface
accessible. When the 14 epitopes were mixed together,
they recalled CD8+ T cell responses in volunteers with
different HLA supertypes providing a reagent useful for
measuring CD8+ T cell responses in genetically different
populations.
Further testing of the NMRC-M3V-Ad-PfCA vaccine
in volunteers representing different HLA A and B super-
types would provide the opportunity to identify addi-
tional class I epitopes. This could support the design of
a chimeric AMA1 molecule able to elicit broadly protec-
tive responses among an HLA diverse population.
Determining the potential contribution of these epitopes
for inducing protective responses awaits future testing
of the NMRC-M3V-Ad-PfCA vaccine in challenge
studies.
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